NDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CALAN SR (verapamil hydrochloride) by Pfizer is mechanism of action essential hypertension verapamil exerts antihypertensive effects by decreasing systemic vascular resistance, usually without orthostatic decreases in blood pressure or reflex tachycardia; bradycardia (rate less than 50 beats/min) is uncommon (1. Approved for cardiovascular disease. First approved in 1986.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CALAN SR (verapamil hydrochloride) is an oral extended-release calcium channel blocker approved in 1986 for treating essential hypertension and angina. It works by inhibiting calcium influx through slow channels, reducing systemic vascular resistance, dilating coronary arteries, and slowing AV node conduction. The drug is particularly effective for vasospastic (Prinzmetal's) angina and reduces cardiac workload without increasing heart rate.
$50KPart D
LOE ApproachingDeclining
As LOE approaches, the brand team is likely consolidating; commercial roles may shift to generic transition planning or be reallocated to growth-stage assets.
Mechanism of Action
Mechanism of action Essential hypertension Verapamil exerts antihypertensive effects by decreasing systemic vascular resistance, usually without orthostatic decreases in blood pressure or reflex tachycardia; bradycardia (rate less than 50 beats/min) is uncommon (1.4%). During isometric or dynamic…
Worked on CALAN SR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.